Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Specialty Generics Market Size Worth $174.9 Billion by 2025: Grand View Research, Inc.

Grand View Research,Inc.
Posted on: 09 Oct 17
Specialty Generics Market Size Worth $174.9 Billion by 2025: Grand View Research, Inc.

PR Newswire

SAN FRANCISCO, October 9, 2017

SAN FRANCISCO, October 9, 2017 /PRNewswire/ --

The global specialty generics market is expected to reach USD 174.9 billion by 2025, according to a new report by Grand View Research, Inc. Rise in demand for low-cost generic specialty drugs is a major factor estimated to accelerate the market growth during the forecast period. Introduction of cost-effective drugs for the treatment of multiple sclerosis, cancer, and other infectious diseases is expected to showcase huge opportunities for the specialty generic drug manufacturers. According to U.S. FDA, generic drugs cost 80% to 85% lower as compared to branded drugs. One of the factors contributing to their affordable price is that they do not need to repeat expensive clinical trials, advertising, and promotional activities. Thus, low cost of generic specialty drugs is expected to accelerate the demand for these medicines.

     (Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )

Rise in number of off-patent specialty drugs is another major factor expected to support growth of the specialty generic drugs market. For instance, the patent for Gilenya, a blockbuster drug by Novartis, will expire in 2019. This drug led to USD 3.1 billion in sales in 2016 for Novartis, with 14% sales growth. In April 2017, Novartis failed to acquire patent extension for Gilenya till 2026 in the U.S. Federal Circuit. Such early patent expirations are expected to boost the entry of new generics.

Browse full research report with TOC on " Specialty Generics Market Analysis By Type (Injectables, Oral), By Application (Oncology, Inflammatory Conditions, Multiple Sclerosis, Hepatitis C), By End-use, And Segment Forecasts, 2014 - 2025 " at: http://www.grandviewresearch.com/industry-analysis/specialty-generics-market

Further Key Findings From the Report Suggest:  

  • In 2016, injectables was the largest revenue-grossing segment in the market due to its high usage and efficacy in treatment of severe chronic diseases
  • The oncology segment accounted for the largest revenue share in 2016 and is expected to maintain its dominance during the forecast period due to worldwide rise in cancer prevalence
  • The specialty pharmacy was the largest revenue-generating segment in end use and is estimated to maintain its dominance during the forecast period. This is due to the fact that specialty pharmacies are dedicated to distribution of highlycomplex, costly, and high-touch medicine
  • North America dominated the total market in 2016 primarily due to the presence of highly developed healthcare infrastructure and local presence of large number of established pharmaceutical companies
  • The Asia Pacific market is estimated to grow at the highest growth rate during the forecast period. Rising prevalence of chronic diseases, developing healthcare infrastructure, and escalating disposable income in Asian countries, such as China and India, are major factors that can be attributed to the growth
  • Some of the major players are Teva Pharmaceuticals USA, Inc.; Mylan N.V.; Sandoz International GmbH; Akorn, Inc.; Mallinckrodt; Valeant Pharmaceuticals International, Inc.; Pfizer, Inc.; Endo Pharmaceuticals, Inc.; Apotex Corp.; Sun Pharmaceutical Industries Ltd.

Browse related reports by Grand View Research: 

Grand View Research has segmented the global specialty generic drugs market on the basis of type, application, end-use, and region: 

  • Type Outlook (Revenue, USD Billion; 2014 - 2025) 
    • Injectables
    • Oral
    • Others
  • Application Outlook (Revenue, USD Billion; 2014 - 2025) 
    • Oncology
    • Inflammatory conditions
    • Multiple sclerosis
    • Hepatitis C
    • Others
  • End-use Outlook (Revenue, USD Billion; 2014 - 2025) 
    • Specialty pharmacy
    • Retail pharmacy
    • Hospital pharmacy
  • Regional Outlook (Revenue, USD Billion; 2014 - 2025) 
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa
      • Saudi Arabia

Read Our Blog By Grand View Research : http://www.grandviewresearch.com/blogs/healthcare

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

SOURCE Grand View Research, Inc.

PR Newswire
www.prnewswire.com

Last updated on: 09/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.